• 1
    Herzog AG, Klein P, Ransil B. Three patterns of catamenial epilepsy. Epilepsia 1997;38:10828.
  • 2
    Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:4314.
  • 3
    Smith SS, Woolley CS. Cellular and molecular effects of steroid hormones on CNS excitability. Cleve Clin J Med 2004;71(suppl. 2):S410.
  • 4
    Herzog A. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:16602.
  • 5
    Herzog A. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999;52:19178.
  • 6
    Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397428.
  • 7
    Harden CL, Pulver MC, Ravdin L, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 1999;40:14027.
  • 8
    Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; in press.
  • 9
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:32133.
  • 10
    Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 1998;51:9448.
  • 11
    Honein MA, Paulozzi LJ, Mathews TJ, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:29816.
  • 12
    MRC Vitamin Study Research Group. Prevention of neural-tube defects: results of the Medical Researdh Council Vitamin Study. Lancet 1991;338:1317.
  • 13
    Hernandez-Diaz S, Werler M, Walker A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:160814.
  • 14
    Nambisan M, Wyszynski DF, Holmes LB. No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk for congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Defects Res 2003;67:5.
  • 15
    Vajda FJ, O'Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003;10:5439.
  • 16
    Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. Br Med J 2000;321:6745.
  • 17
    Holmes LB. The teratogenecity of anticonvulsant drugs: a progress report. J Med Genet 2002;39:2457.
  • 18
    Pennell PB. The importance of monotherapy in pregnancy. Neurology 2003;60:S318.
  • 19
    Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004;45:14634.
  • 20
    Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004;61:6738.
  • 21
    Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:9615.
  • 22
    Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 2004;45:1465.
  • 23
    Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:1938.
  • 24
    Isojarvi JI, Cunnington M, Messenheimer JA. Twelve years of monitoring through an inernational observational study of pregnancy outcomes folowing exposure to lamotrigine (abstract). Epilepsia 2005;46(suppl. 6): 110.
  • 25
    Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67:40712.
  • 26
    Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004;11:8548.
  • 27
    Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005;112:13743.
  • 28
    Vajda FJ, O'Brien TJ, Hitchcock A, et al. Australian pregnancy registry of women on antiepileptic drugs: 5 year results (abstract). Epilepsia 2004; 45(suppl. 7): 234.
  • 29
    Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S3542.
  • 30
    Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004;62:2925.
  • 31
    Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005;65:1858.
  • 32
    Pennell P, Montgomery J, Clements S, et al. Lamotrigine clearance markedly increases during pregnancy. Epilepsia 2002;43:234.
  • 33
    De Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:5713.
  • 34
    Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:5701.
  • 35
    Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005;46:14147.
  • 36
    Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006;66:35460.
  • 37
    Meador KJ, Zupanc ML. Neurodevelopmental outcomes of children born to mothers with epilepsy. Cleve Clin J Med 2004;71(suppl. 2):S3841.
  • 38
    Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:1521.
  • 39
    Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:2832.
  • 40
    Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:157583.
  • 41
    Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:94954.
  • 42
    Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343:11826.
  • 43
    Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:77689.
  • 44
    Morrell M. Guidelines for the care of women with epilepsy. Neurology 1998;51:S217.
  • 45
    Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonata and during lactation. Epilepsia 2000;41:70913.
  • 46
    Pennell PB, Ritchie JC, Newport DJ, et al. Pharmacokinetics of lamotrigine excretion into human breast milk (abstract). Neurology . 2006; 66(suppl. 2): A723.
  • 47
    Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005;46:7757.